tolvaptan has been researched along with yohimbine in 1 studies
| Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) | Studies (yohimbine) | Trials (yohimbine) | Recent Studies (post-2010) (yohimbine) |
|---|---|---|---|---|---|
| 967 | 172 | 786 | 5,893 | 253 | 532 |
| Protein | Taxonomy | tolvaptan (IC50) | yohimbine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.02 | |
| D(2) dopamine receptor | Homo sapiens (human) | 2.06 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0466 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.126 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.013 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.126 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.074 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.689 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huigens, RW; Luesch, H; Norwood, VM; Paciaroni, NG; Ratnayake, R | 1 |
1 other study(ies) available for tolvaptan and yohimbine
| Article | Year |
|---|---|
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
Topics: Antineoplastic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Yohimbine | 2020 |